Search
Rapport Therapeutics Inc
RAPPAdd to Watchlist
48.360USD
+0.940+1.98%
Close 08-17 16:00（ET）Quotes delayed by 15 min
2.32BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Rapport Therapeutics Inc is 8.92, ranking 33 out of 387 in the Biotechnology & Medical Research industry. The average price target is 50.00, with a high of 80.00 and a low of 40.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
60.091
Target Price
+26.72%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Rapport Therapeutics Inc
RAPP
13
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Rapport Therapeutics Inc's price target?
Analysts forecast that Rapport Therapeutics Inc's price target is USD 50.00, with the highest forecast at USD 80.00 and the lowest forecast at USD 40.00.
How have Rapport Therapeutics IncRAPP's recent earnings per share performed?
The market expectation was USD -1.19, while Rapport Therapeutics IncRAPP's earnings per share (EPS) for the previous quarter was USD -0.42. EPS for the next quarter is expected at USD -1.11.
What is the analyst rating for Rapport Therapeutics Inc?
Based on the ratings of Rapport Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.